Corona Remedies Limited Files DRHP with SEBI for ₹800 Crore IPO

Corona Remedies Limited, a pharmaceutical company focused on women’s healthcare, cardio-diabeto, pain management, and urology, has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise up to ₹800 crore through an initial public offering (IPO).

IPO Details

• The entire ₹800 crore is an Offer For Sale.
• The equity shares are proposed to be listed on BSE and NSE.
• JM Financial Limited, IIFL Capital Services Limited, and Kotak Mahindra Capital Company Limited are the Book Running Lead Managers to the issue.

Corona Remedies Limited is backed by ChrysCapital affiliate and Sepia Investments, and is engaged in developing, manufacturing, and marketing pharmaceutical products in various therapeutic areas.